Karuna Therapeutics Inc
Change company Symbol lookup
Select an option...
KRTX Karuna Therapeutics Inc
SNSE Sensei Biotherapeutics Inc
ALGS Aligos Therapeutics Inc
SRRA Sierra Oncology Inc
ATOS Atossa Therapeutics Inc
OSMT Osmotica Pharmaceuticals PLC
SAND Sandstorm Gold Ltd
GRVI Grove Inc
STON Stonemor Inc
TK Teekay Corp
Go

Health Care : Biotechnology | Small Cap Value
Company profile

Karuna Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on to create and deliver transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate, KarXT, is an oral modulator of muscarinic receptors that are located both in the central nervous system (CNS) and various peripheral tissues. It is initially developing KarXT, for the treatment of acute psychosis in patients with schizophrenia. The Company is developing a pipeline of therapeutic programs to address symptoms associated with schizophrenia and psychosis associated with Alzheimer’s disease (AD), as well as various forms of pain. KarXT is a combination of xanomeline and trospium. KarXT combines xanomeline, a muscarinic agonist, with trospium, a muscarinic antagonist, to stimulate muscarinic receptors in the CNS. It is advancing a pipeline of therapeutic programs to address the positive, negative and cognitive symptoms.

Price
Delayed
$123.87
Day's Change
-0.74 (-0.59%)
Bid
--
Ask
--
B/A Size
--
Day's High
125.49
Day's Low
121.22
Volume
(Light)

Today's volume of 27,849 shares is on pace to be much lighter than KRTX's 10-day average volume of 191,081 shares.

27,849

Boston Beer Shareholder Notice

6:56 pm ET October 15, 2021 (Newsfile) Print

New York, New York--(Newsfile Corp. - October 15, 2021) -  Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against The Boston Beer Company, Inc. ("Boston Beer" or the "Company") (NYSE: SAM) and reminds investors of the November 15, 2021 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

If you suffered losses exceeding $100,000 investing in Boston Beer stock or options between April 22, 2021 and September 8, 2021 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). You may also click here for additional information: www.faruqilaw.com/SAM.

Cannot view this image? Visit: https://orders.newsfilecorp.com/files/6455/99882_ebefe46234c0fb12_001.jpg



There is no cost or obligation to you.

Faruqi & Faruqi is a leading minority and Woman-owned national securities law firm with offices in New York, Delaware, Pennsylvania, California and Georgia.

As detailed below, the lawsuit focuses on whether the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose: (1) that Boston Beer's hard seltzer sales were decelerating; (2) that, as a result, Boston Beer was reasonably likely to incur inventory write-offs; (3) that the Company was reasonably likely to incur shortfall fees payable to third party brewers; (4) that, as a result of the foregoing, Boston Beer's financial results would be adversely impacted; and (5) that, as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

On July 22, 2021, after the market closed, Boston Beer reduced its full year 2021 guidance, expecting earnings per share between $18 and $22, down from a prior range of $22 and $26. The Company cited softer-than-expected sales in the hard seltzer category and overall beer industry and also stated that it had "overestimated the growth of the hard seltzer category in the second quarter."

On this news, the Company's share price fell $246.54, or 26%, to close at $701.00 per share on July 23, 2021, on unusually heavy trading volume.

On September 8, 2021, after the market closed, Boston Beer withdrew its 2021 financial guidance, citing decelerating sales of hard seltzer products. The Company also stated that it "expects to incur hard seltzer-related inventory write-offs, shortfall fees payable to 3rd party brewers, and other costs" for the remainder of fiscal 2021.

On this news, the Company's share price fell $21.09, or 3.7%, to close at $538.31 per share on September 9, 2021, on unusually heavy trading volume.

The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.

Faruqi & Faruqi, LLP also encourages anyone with information regarding Boston Beer's conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/99882

comtex tracking

COMTEX_395289572/2523/2021-10-15T18:56:58

Earnings Calendar and Events Data provided by |Terms of Use| © 2021 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2021. All rights reserved.